terça-feira, 6 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleCB Insights

Executive Interview: Covecta

View original at cbinsights.com
CB Insights - Enterprise Ai Title: Executive Interview: Covecta Date: 2026-08-18 17:42 Source: https://www.cbinsights.com/research/executive-interview-covecta/ <h4><strong><a href="https://app.cbinsights.com/profiles/p/e53BV/Current">Ben Thomas</a> , Chief Revenue Officer at <a href="https://app.cbinsights.com/profiles…
Opening lines of the source · CB Insights · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Covecta solves problems across workforce productivity, workflow automation, and portfolio management by deploying seasoned banker agents that handle mission-critical tasks, workflows, and portfolio activities beyond what generalized AI can do.

    60% confidence
  • Covecta serves corporate and commercial banks, specialist non-bank lenders, building societies, credit unions, and private credit organizations, currently across the US and UK, with plans to expand globally.

    60% confidence
  • Covecta's total addressable market is tens of thousands of financial institutions globally, and the company aims to disrupt not just their software budget but their labor budget as well.

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com